Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome

Author's Avatar
Dec 15, 2020
Article's Main Image

PR Newswire